Janux Therapeutics (JANX) Net Margin (2021 - 2025)
Janux Therapeutics (JANX) has disclosed Net Margin for 5 consecutive years, with 243.13% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin rose 614844.0% to 243.13% in Q3 2025 year-over-year; TTM through Dec 2025 was 1136.25%, a 48463.0% decrease, with the full-year FY2025 number at 1136.25%, down 48463.0% from a year prior.
- Net Margin was 243.13% for Q3 2025 at Janux Therapeutics, up from 6391.57% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 66.98% in Q2 2024 to a low of 6391.57% in Q3 2024.
- A 5-year average of 1126.13% and a median of 837.06% in 2021 define the central range for Net Margin.
- Peak YoY movement for Net Margin: crashed -593198bps in 2024, then soared 614844bps in 2025.
- Janux Therapeutics' Net Margin stood at 830.2% in 2021, then surged by 32bps to 564.67% in 2022, then increased by 15bps to 477.77% in 2023, then crashed by -1238bps to 6391.57% in 2024, then soared by 96bps to 243.13% in 2025.
- Per Business Quant, the three most recent readings for JANX's Net Margin are 243.13% (Q3 2025), 6391.57% (Q3 2024), and 66.98% (Q2 2024).